Adalvo acquires Enzene romiplostim biosimilar programme targeting global Nplate market
Adalvo has acquired Enzene's romiplostim biosimilar programme, expanding its complex biologics portfolio with a candidate referencing Nplate for immune thrombocytopenia.
The agreement transfers the romiplostim biosimilar programme to Adalvo while Enzene remains responsible for development and manufacturing support, including preparation for potential regulatory submissions in the United States, Europe and other markets.
The acquisition targets a reference medicine reported to have generated approximately $1.5 billion in global sales in 2025, although transaction consideration was not disclosed and the biosimilar has not received a new US or EU approval through this announcement.
Field | Content |
Article Type | Deals |
Acquirer | Adalvo |
Programme Seller | Enzene |
Deal Type | Biosimilar development programme acquisition |
Announcement Date | 27 October 2026 |
Acquired Programme | Romiplostim biosimilar programme |
Reference Medicine | Nplate |
Reference Active Ingredient | Romiplostim |
Therapeutic Area | Haematology |
Target Indication | Immune thrombocytopenia |
Product Category | Investigational biosimilar |
Development and Manufacturing Partner | Enzene |
Partner Responsibilities | Continued development and manufacturing support |
Prospective Regulatory Markets | United States; European Union; other international markets |
Regulatory Status | Future regulatory submissions anticipated; no new US or EU biosimilar approval announced |
Acquisition Consideration | Not disclosed |
Reference Product Global Sales | Approximately $1.5 billion in 2025 according to the companies |
Manufacturing Geography | India |
What Happened | Adalvo acquired Enzene's romiplostim biosimilar programme while retaining Enzene as development and manufacturing partner. |
Why It Matters | The transaction expands Adalvo's biosimilars portfolio into a complex biological treatment area with an established reference medicine market. |
Strategic Rationale | Develop a biosimilar alternative to romiplostim for international markets using Enzene's development and manufacturing capabilities. |
Commercial Context | The companies reported approximately $1.5 billion in 2025 global sales for the reference medicine. |
Key Takeaway | Adalvo has acquired an investigational romiplostim biosimilar programme, not an approved biosimilar product; financial terms remain undisclosed. |
What to Watch | Development milestones, comparability studies, regulatory submissions, manufacturing readiness and future commercial partnerships. |
Primary Source | Enzene |
Primary Source URL | https://www.enzene.com/news/adalvo-expands-biosimilars-portfolio-through-acquisition-of-romiplostim-biosimilar-programme-from-enzene/ |
Relevant Date | 27 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare